FDA approves BIMZELX, a dual IL-17A/F inhibitor, for treating multiple inflammatory diseases.
The FDA has approved BIMZELX (bimekizumab-bkzx) for treating active psoriatic arthritis, non-radiographic axial spondyloarthritis with inflammation, and ankylosing spondylitis in adults. It is the first IL-17A and IL-17F inhibitor authorized in the U.S. for these conditions, highlighting its potential benefits for patients with chronic inflammatory diseases. UCB, the manufacturer, emphasizes the advantages of dual inhibition in improving treatment outcomes.
September 23, 2024
7 Articles